• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

钠-葡萄糖协同转运蛋白 2（SGLT-2）抑制剂在射血分数降低或保留的心力衰竭患者中是否具有相似的心血管获益？

Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?

机构信息

Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India.

Department of Diabetes, Fortis-CDOC hospital for Diabetes & Allied Science, New Delhi, India.

出版信息

J Diabetes. 2021 Jul;13(7):596-600. doi: 10.1111/1753-0407.13182. Epub 2021 Apr 21.

DOI:10.1111/1753-0407.13182
PMID:33792199
Abstract

Highlights The beneficial cardiovascular (CV) effects of SGLT-2 inhibitors (SGLT-2i) in patients with heart failure are already known. Whether SGLT-2i exert similar CV effects in heart failure with reduced or preserved ejection fraction is not known. This meta-analysis showed SGLT-2i exert similar CV benefits irrespective of the types of heart failure. Future trials will confirm or refute the CV effects of SGLT-2i in patients with heart failure with preserved ejection fraction.

摘要

要点 SGLT-2 抑制剂（SGLT-2i）对心力衰竭患者的心血管（CV）有益作用已为人所知。但 SGLT-2i 是否对射血分数降低或保留的心衰患者有类似的 CV 作用尚不清楚。本荟萃分析表明，SGLT-2i 发挥了相似的 CV 获益，而与心力衰竭的类型无关。未来的试验将证实或反驳 SGLT-2i 在射血分数保留的心衰患者中的 CV 作用。

相似文献

1
Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?钠-葡萄糖协同转运蛋白 2（SGLT-2）抑制剂在射血分数降低或保留的心力衰竭患者中是否具有相似的心血管获益？
J Diabetes. 2021 Jul;13(7):596-600. doi: 10.1111/1753-0407.13182. Epub 2021 Apr 21.
2
Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.在伴有或不伴有 2 型糖尿病的心力衰竭患者中 SGLT-2 抑制剂的心血管结局：随机对照试验的系统评价和荟萃分析。
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):351-359. doi: 10.1016/j.dsx.2021.01.006. Epub 2021 Jan 20.
3
Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?钠-葡萄糖协同转运蛋白 2（SGLT-2）抑制剂在射血分数降低的心力衰竭伴 2 型糖尿病、糖尿病前期和血糖正常的患者中是否具有相似的心血管获益？
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102282. doi: 10.1016/j.dsx.2021.102282. Epub 2021 Sep 16.
4
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?钠-葡萄糖协同转运蛋白 2 抑制剂治疗心力衰竭患者：近期我们有何新认识？
Curr Atheroscler Rep. 2022 Aug;24(8):627-634. doi: 10.1007/s11883-022-01038-2. Epub 2022 Jun 2.
5
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂与有无心力衰竭病史患者的心血管结局：一项系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 3;8(6):557-567. doi: 10.1093/ehjcvp/pvac001.
6
Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.钠-葡萄糖共转运蛋白 2 抑制剂对伴有心血管疾病患者的心血管、肾脏和安全性结局的影响：一项随机对照试验的荟萃分析。
Cardiovasc Diabetol. 2021 Apr 22;20(1):83. doi: 10.1186/s12933-021-01272-z.
7
Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.钠-葡萄糖协同转运蛋白 2 抑制剂对心力衰竭患者心血管结局的影响：一项随机对照试验的荟萃分析。
Eur J Intern Med. 2021 May;87:20-28. doi: 10.1016/j.ejim.2021.03.020. Epub 2021 Apr 3.
8
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.钠-葡萄糖协同转运蛋白 2 抑制剂在心力衰竭患者中的应用：五项随机对照试验的综合荟萃分析。
Lancet. 2022 Sep 3;400(10354):757-767. doi: 10.1016/S0140-6736(22)01429-5. Epub 2022 Aug 27.
9
Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.钠-葡萄糖共转运蛋白 2 抑制剂可诱导重症心力衰竭患者心外膜脂肪组织的抗炎和抗铁死亡转化。
Cardiovasc Diabetol. 2024 Jun 28;23(1):223. doi: 10.1186/s12933-024-02298-9.
10
Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.2型糖尿病患者中与钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂及其他降糖药物相关的心血管结局：一项真实世界的系统评价和荟萃分析
PLoS One. 2021 Feb 19;16(2):e0244689. doi: 10.1371/journal.pone.0244689. eCollection 2021.

引用本文的文献

1
Meta-analysis of the efficacy and safety of SGLT-2 inhibitors in patients with heart failure and type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂治疗心力衰竭合并2型糖尿病患者疗效与安全性的Meta分析
Medicine (Baltimore). 2025 May 2;104(18):e42196. doi: 10.1097/MD.0000000000042196.
2
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews.钠-葡萄糖共转运蛋白 2 抑制剂在射血分数轻度降低或保留的心衰中的疗效和安全性：36 项系统评价概述。
Heart Fail Rev. 2023 Sep;28(5):1033-1051. doi: 10.1007/s10741-023-10324-3. Epub 2023 Jun 7.
3
Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses.
钠-葡萄糖协同转运蛋白2抑制剂用于射血分数保留的心力衰竭的科学证据：系统评价和荟萃分析的伞状综述
Front Cardiovasc Med. 2023 May 12;10:1143658. doi: 10.3389/fcvm.2023.1143658. eCollection 2023.
4
Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂治疗射血分数保留的心力衰竭的潜在机制
Front Physiol. 2021 Nov 5;12:752370. doi: 10.3389/fphys.2021.752370. eCollection 2021.
5
Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.射血分数保留或处于中间范围的心力衰竭患者中的糖尿病与SGLT2抑制剂
Heart Fail Rev. 2023 May;28(3):683-695. doi: 10.1007/s10741-021-10186-7. Epub 2021 Nov 1.